ArticleHepatology communications2025
Electronic decision aids enhance management of primary care patients with steatotic liver disease: Proof of concept pilot study.
Article in Hepatology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07382349 (Randomized Controlled Trial of Electronic Clinical Decision Support Systems for Improving Care Management and Clinical Outcomes for Adults With Steatotic Liver Disease), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial of Electronic Clinical Decision Support Systems for Improving Care Management and Clinical Outcomes for Adults With Steatotic Liver Disease
Who cites it
3 citing papers in PubMed.
- Predictive modeling and clinical decision tools for risk stratification in steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Review
- Risk stratification of MASLD/MASH in type 2 diabetes: a pragmatic endocrinology outpatient pathway.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe approach to appropriate risk stratification for metabolic dysfunction-associated steatotic liver disease (MASLD) is variable, and the adoption of non-invasive liver disease assessments in clinical practice is suboptimal. In this study, we implemented an electronic decision support tool for primary care patients with MASLD to assess its influence on linkage to care.
methodsWe performed a prospective, before-and-after pilot study in which post-implementation providers were presented with an electronic decision aid automating non-invasive liver disease assessments with the Fibrosis-4 score and providing individualized, guideline-directed recommendations. Patients were included if attending an outpatient primary care visit with a study provider, had a pre-existing diagnostic code for MASLD, and had not established care with a hepatologist in the 3 years before the office visit. The primary outcome was linkage to care, defined as adherence to guideline-directed recommendations for the next step of care. A total of 503 encounters were included, accounting for 301 unique patients.
resultsProvider adherence to guideline-directed clinical recommendations increased from 29.7% to 45.8% post-implementation (p<0.001). The effect of this intervention remained significant when controlling for patient age, race, sex, resident physician involvement in the clinic visit, and concomitant comorbidities of diabetes, hypertension, and hyperlipidemia (OR 2.11 [95% CI 1.42-3.14]; p<0.001). There was a modest increase in the number of referrals to hepatology post-implementation (2.3%-7.1%; OR 3.27 [95% CI 1.33-9.18]; p=0.014).
conclusionsIn conclusion, we present a novel, electronically integrated, innovative methodology for direct delivery of individualized guidance for the management of patients with MASLD that significantly enhanced the direction of care toward necessary guideline-directed liver assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.